JYNT (The Joint) Altman Z2-Score: 1.42 (As of Jun. 27, 2026)


JYNT The Joint Corp JYNT
64 GF Score
Price $8.52
GF Value $11.11
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is The Joint Altman Z2-Score?

The Joint JYNT -7.49% 64 Altman Z2-Score is 1.42 as of Jun. 27, 2026. GuruFocus rates JYNT with a GF Score™ of 64/100 and a GF Value™ of $11.11 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 678 Healthcare Providers & Services companies, The Joint ranks worse than 57.96% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

The Joint has a Altman Z2-Score of 1.42, indicating it is in Grey Zones. This implies that The Joint is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for The Joint's Altman Z2-Score or its related term are showing as below:

JYNT' s Altman Z2-Score Range Over the Past 10 Years
Min: -10.8   Med: -0.14   Max: 1.87
Current: 1.42

During the past 13 years, The Joint's highest Altman Z2-Score was 1.87. The lowest was -10.80. And the median was -0.14.


The Joint  (NAS:JYNT) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


The Joint Altman Z2-Score Related Terms


The Joint Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for The Joint's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Joint Altman Z2-Score Chart

The Joint Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.96 -0.21 0.43 1.15 1.07

The Joint Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 1.74 1.87 1.07 1.42

JYNT vs MAHN, WW, PARK: Altman Z2-Score Comparison

For the Medical Care Facilities subindustry, The Joint's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Joint Altman Z2-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Joint's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where The Joint's Altman Z2-Score falls into.


JYNT
64GF Score
The Joint Corp JYNT
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The Joint Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

The Joint's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.3353+3.26*-0.4057+6.72*0.0238+1.05*0.3646
=1.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was $57.92 Mil.
Total Current Assets was $49.59 Mil.
Total Current Liabilities was $30.17 Mil.
Retained Earnings was $-23.50 Mil.
Pre-Tax Income was 1.114 + 0.941 + 0.301 + -0.978 = $1.38 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Liabilities was $42.43 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(49.591 - 30.171)/57.921
=0.3353

X2=Retained Earnings/Total Assets
=-23.496/57.921
=-0.4057

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(1.378 - 0)/57.921
=0.0238

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(15.469 - 0)/42.427
=0.3646

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

The Joint has a Altman Z2-Score of 1.42 indicating it is in Grey Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 1.42 mean?
The Joint (JYNT) has a Altman Z2-Score of 1.42 as of Jun. 27, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on The Joint and its competitors. According to the industry distribution chart, The Joint ranks #393 out of 678 companies in the Healthcare Providers & Services industry, placing it in the top 58%.
Is The Joint's Altman Z2-Score too high?
The Joint's current Altman Z2-Score is 1.42. The Healthcare Providers & Services industry median Altman Z2-Score is 2.17. The Joint's value of 1.42 is 34.4% below this industry median. Based on the distribution chart, The Joint ranks #393 out of 678 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, The Joint has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Joint's Altman Z2-Score compare to MAHN and WW?
According to the Healthcare Providers & Services industry distribution chart, The Joint ranks #393 out of 678 companies for Altman Z2-Score. This places The Joint in the lower half of its industry. The industry median Altman Z2-Score is 2.17. The Joint's value of 1.42 is 34.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Healthcare Providers & Services company?
The median Altman Z2-Score among Healthcare Providers & Services companies is 2.17, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Joint's current Altman Z2-Score of 1.42 is 34.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on The Joint and its competitors. For the Healthcare Providers & Services industry, the median Altman Z2-Score is 2.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Joint's current Altman Z2-Score is 1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Joint stock overvalued right now?
Based on GuruFocus' analysis, The Joint (JYNT) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.11, compared to a current price of $8.52 — trading 23.3% below its estimated fair value. The current Altman Z2-Score is 1.42 and 34.4% below the Healthcare Providers & Services industry median of 2.17. The Joint's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For The Joint (JYNT), the current Altman Z2-Score is 1.42 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is The Joint (JYNT) Overvalued in 2026?

Based on GuruFocus' analysis, The Joint stock appears to be undervalued. The current stock price of $8.52 is trading 23.3% below its estimated GF Value™ of $11.11. GuruFocus considers The Joint to be Modestly Undervalued.

Key valuation signals for JYNT:

  • Altman Z2-Score: 1.42
  • GF Value™: $11.11 vs. price of $8.52 (23.3% below fair value)
  • GF Score™: 64/100 with 4 warning signs
  • Industry Position: 34.4% below the Healthcare Providers & Services median (#393 of 678)

No single metric tells the full story. See the JYNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


The Joint Business Description

Address 16767 North Perimeter Drive, Suite 110, Scottsdale, AZ, USA, 85260
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
64GF Score

Get the complete analysis for JYNT

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.52
Price
$11.11
GF Value